Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. Hammons L, et al. Among authors: narra r. Haematologica. 2024 Mar 1;109(3):906-914. doi: 10.3324/haematol.2023.283590. Haematologica. 2024. PMID: 37646658 Free PMC article.
Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Guru Murthy GS, et al. Among authors: narra r. Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833. doi: 10.1016/j.bbmt.2018.12.069. Epub 2018 Dec 18. Biol Blood Marrow Transplant. 2019. PMID: 30572109 Free article.
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN. Chhabra S, et al. Among authors: narra rk. Biol Blood Marrow Transplant. 2020 May;26(5):893-901. doi: 10.1016/j.bbmt.2020.01.010. Epub 2020 Jan 23. Biol Blood Marrow Transplant. 2020. PMID: 31982543 Free article.
Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.
Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN. Dhakal B, et al. Cancer. 2020 Jun 15;126(12):2791-2801. doi: 10.1002/cncr.32831. Epub 2020 Mar 10. Cancer. 2020. PMID: 32154922 Free article.
Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.
Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B. Hammons L, et al. Among authors: narra r. Br J Haematol. 2024 Mar;204(3):887-891. doi: 10.1111/bjh.19244. Epub 2023 Dec 6. Br J Haematol. 2024. PMID: 38054558
65 results